BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22147992)

  • 21. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y; Shimizu S; Takehara T; Harada M
    J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
    Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
    Reyes R; Wani NA; Ghoshal K; Jacob ST; Motiwala T
    Gene Expr; 2017 Feb; 17(2):129-140. PubMed ID: 27938509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
    J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes.
    Nunes M; Shi C; Greenberger LM
    Mol Cancer Ther; 2004 Jan; 3(1):21-7. PubMed ID: 14749472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
    Wu CH; Wu X; Zhang HW
    J Surg Res; 2016 Dec; 206(2):371-379. PubMed ID: 27884331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
    Gao Y; Li HX; Xu LT; Wang P; Xu LY; Cohen L; Yang PY; Gu K; Meng ZQ
    Mol Biol Rep; 2012 Feb; 39(2):1683-9. PubMed ID: 21617941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
    Fernando J; Sancho P; Fernández-Rodriguez CM; Lledó JL; Caja L; Campbell JS; Fausto N; Fabregat I
    J Cell Physiol; 2012 Apr; 227(4):1319-25. PubMed ID: 21604268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
    Ruan ZP; Xu R; Lv Y; Tian T; Wang WJ; Guo H; Nan KJ
    Oncol Res; 2012; 20(2-3):113-21. PubMed ID: 23193917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
    Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
    Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.